It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
The goal for the project is the identification and optimization of anti-viral compounds.
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Subscribe To Our Newsletter & Stay Updated
